Multivesicular liposomal depot system for sustained delivery of risperidone: development, characterization, and toxicity assessment

Alavi, Sonia; Mahjoob, Mohammad A.; Haeri, Azadeh; Shirazi, Farshad H.; Abbasian, Zahra; Dadashzadeh, Simin

doi:10.1080/03639045.2021.1989454

Cited by 6 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the hemolysis assay, DepoDOX revealed a hemolysis index of 1.47% which confirms the hemocompatibility of the prepared formulation. Nearly identical results have been reported by Alavi et al for risperidoneloaded MVLs (41), supporting the biocompatibility of the investigated vesicles.…”

Section: Selected Formulation For Additional In Vitro Experimentssupporting

confidence: 90%

“…A limited number of studies have been performed to investigate drug-carrier interactions via FTIR analysis for MVL carriers. In a study by Alavi et al ( 41 ) on risperidone, similar results were obtained in the FTIR diagram. These results indicated that free drug peaks are eliminated, and the spectrum of the drug-loaded carrier is very similar to the empty carrier spectrum.…”

Section: Discussionsupporting

confidence: 70%

See 1 more Smart Citation

Doxorubicin-Loaded Multivesicular Liposomes (DepoFoam) as a Sustained Release Carrier Intended for Locoregional Delivery in Cancer Treatment: Development, Characterization, and Cytotoxicity Evaluation

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background: Despite the advantages of direct intratumoral (IT) injection, the relatively rapid withdrawal of most anti-cancer drugs from the tumor due to their small molecular size limits the effectiveness of this method of administration. To address these limitations, recently, increasing attention has been directed to using slow-release biodegradable delivery systems for IT injection. Objectives: This study aimed to develop and characterize a doxorubicin-loaded DepoFoam system as an efficient controlled-release carrier to be employed for locoregional drug delivery in cancer treatment. Methods: Major formulation parameters, including the molar ratio of cholesterol to the main lipid [Chol/egg phosphatidylcholine (EPC)], triolein (TO) content, and lipid-to-drug molar ratio (L/D), were optimized using a two-level factorial design approach. The prepared batches were evaluated for encapsulation efficiency (EE) and percentage of drug release (DR) after 6 and 72 hours as dependent variables. The optimum formulation (named DepoDOX) was further evaluated in terms of particle size, morphology, zeta potential, stability, Fourier-transform infrared spectroscopy, in vitro cytotoxicity, and hemolysis. Results: The analysis of factorial design indicated that TO content and L/D ratio had a negative effect on EE; between these two, TO content had the greatest effect. The TO content was also the most significant component, with a negative effect on the release rate. The ratio of Chol/EPC showed a dual effect on the DR rate. Using a higher percentage of Chol slowed down the initial release phase of the drug; nevertheless, it accelerated the DR rate in the later slow phase. DepoDOX were spherical and honeycomb-like structures (≈ 9.81 μm) with a desired sustained release profile, as DR lasted 11 days. Its biocompatibility was confirmed by the results of cytotoxicity and hemolysis assays. Conclusions: The in vitro characterization of optimized DepoFoam formulation demonstrated its suitability for direct locoregional delivery. DepoDOX, as a biocompatible lipid-based formulation, showed appropriate particle size, high capability for encapsulating doxorubicin, superior physical stability, and a markedly prolonged DR rate. Therefore, this formulation could be considered a promising candidate for locoregional drug delivery in cancer treatment.

show abstract

Section: Selected Formulation For Additional In Vitro Experimentssupporting

confidence: 90%

Section: Discussionsupporting

confidence: 70%

Doxorubicin-Loaded Multivesicular Liposomes (DepoFoam) as a Sustained Release Carrier Intended for Locoregional Delivery in Cancer Treatment: Development, Characterization, and Cytotoxicity Evaluation

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is evident that increasing the concentration of micellar membrane-forming agents, which in turn increases the number of micelles per unit volume, can cause a significant increase in the amount of cargo incorporated in the carriers. 20,27,42 Although increment of the molar ratio of L/D leads to higher entrapment of POS molecules, the ratio should be selected with care, since high lipid concentrations are not suitable for micelle preparation on an industrial scale.…”

Section: Discussionmentioning

confidence: 99%

Biocompatible phospholipid-based mixed micelles for posaconazole ocular delivery: Development, characterization, and in - vitro antifungal activity

et al. 2022

Self Cite

View full text Add to dashboard Cite

Current study intended to prepare and evaluate phospholipid-based, mixed micelles (MMs) to improve the ocular delivery of posaconazole (POS), a broad-spectrum antifungal drug. For this, MMs based on egg phosphatidylcholine (EPC), as the main component, in combination with various bile salts (sodium cholate (NaC), sodium deoxycholate (NaDC), sodium taurocholate (NaTC)) or non-ionic surfactants (Pluronic® F-127, Pluronic® F-68, Tween 80, Labrasol® ALF, and d-a-tocopheryl polyethylene glycol 1000 succinate (TPGS)) were prepared. Particle size, polydispersity index, zeta potential and entrapment efficiency were evaluated to optimize the composition and preparation method of the MMs. Finally, morphology, stability, in vitro release pattern, and in vitro antifungal activity of the optimized formulation were investigated. Among the prepared MMs, vesicles composed of EPC: TPGS with a molar ratio of 70:30, prepared by the thin-film hydration method, showed more appropriate features. Among the prepared MMs, vesicles composed of EPC: TPGS with a molar ratio of 70:30 showed more appropriate features, including an entrapment efficiency (EE) greater than 80%, spherical shape morphology, an average particle size of about 58 nm, desirable stability over a month, slow-release without a noticeable initial burst, and a significantly higher in vitro antifungal activity in comparison with the drug suspension. Therefore, this formulation was selected as the optimal MMs and could be considered as a promising carrier for topical ocular delivery of POS.

show abstract

Preparation of nano-sized multi-vesicular vesicles (MVVs) and its application in co-delivery of doxorubicin and curcumin

Sun

Liang

Yang

et al. 2023

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

Multivesicular liposomal depot system for sustained delivery of risperidone: development, characterization, and toxicity assessment

Cited by 6 publications

References 42 publications

Doxorubicin-Loaded Multivesicular Liposomes (DepoFoam) as a Sustained Release Carrier Intended for Locoregional Delivery in Cancer Treatment: Development, Characterization, and Cytotoxicity Evaluation

Doxorubicin-Loaded Multivesicular Liposomes (DepoFoam) as a Sustained Release Carrier Intended for Locoregional Delivery in Cancer Treatment: Development, Characterization, and Cytotoxicity Evaluation

Biocompatible phospholipid-based mixed micelles for posaconazole ocular delivery: Development, characterization, and in - vitro antifungal activity

Preparation of nano-sized multi-vesicular vesicles (MVVs) and its application in co-delivery of doxorubicin and curcumin

Contact Info

Product

Resources

About